publicações selecionadas
-
artigo de revista
- The modulatory role of internet-supported mindfulness-based cognitive therapy on extracellular vesicles and psychological distress in people who have had cancer: a protocol for a two-armed randomized controlled study. Trials. 2022
- Secreted extracellular vesicle molecular cargo as a novel liquid biopsy diagnostics of central nervous system diseases. International Journal of Molecular Sciences. 2021
- Sirtuins' Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion. Cancers. 2020
- Overexpression of circulating MiR-30b-5p identifies advanced breast cancer. Journal of Translational Medicine. 2019
- High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: data from regional cervical cancer screening program. Papillomavirus Research. 2019
- A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97. Clinical Epigenetics. 2018
- Influence of HOTAIR rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival. Biomarkers in Medicine. 2018
- SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization. Epigenetics. 2017
- Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget. 2016
- Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication. Epigenetics. 2015
- MicroRNA-375 plays a dual role in prostate carcinogenesis. Clinical Epigenetics. 2015
- Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. Journal of Cellular and Molecular Medicine. 2015
- SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. Oncotarget. 2015
- T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness. Clinical Cancer Research. 2014
- Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate. 2012
- Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immunity. 2012
- Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer.. BMC Cancer. 2011